Phacilitate Vaccine Forum Spring 2002
Presentations
If you would like to purchase the documentation (Only available on CD) please email team@phacilitate.co.uk and we will confirm a price with you.
Day 1 - May 13th 2002
Amie Batson
Accelerating vaccine development and introduction around the World – World Bank Perspective
Dr Kevin A. Bryett
Re-working your business model to achieve customer focus
Mark Chataway
Marketing vaccines
Dr Michael J. Clark
Influencing R&D output efficiency with market information
Dr Peter Hambleton
Vaccines and bioterrorism: Issues and challenges
John Lloyd
Delivery systems for the 21st Century
Dr Anna Lönnroth
Vaccine research – Strategies for research and funding within the Sixth Framework Programme (2002-2006)
Karen O’Keeffe
Case Study – Promoting travel vaccines
Dr Jay Wenger
Keynote Address: World Health Organisation – Immunization and vaccine development 2002-2003 strategic plan
Bruce G. Weniger, MD, MPH
Challenges facing U.S. public sector immunization programs: Innovations we would like to see
DAY 2 - May 14th 2002
Dr Susan W. Barnett
Next generation HIV vaccines for clinical evaluation
Dr Ronald W. Ellis
New technologies and the comparative product development philosophies of big, mid and small vaccine companies
David Gee
The Pharmexa business model
Professor Marc Girard
T Cell Vaccines: a new paradigm for vaccines targeted to chronic viral diseases including AIDS
Nick Higgins
A good deal is about more than just money
Allan P. Jarvis Jr., Ph.D
Roundtable discussion: Partnerships, alliances and licensing deals
Professor Michel Klein
Progress in the development of therapeutic HIV vaccines
Dr Stephen McGarry
Vaccine companies – The bright spot in an underperforming biotech sector
Dr Anya Ramalho
Roundtable discussion: Partnerships, alliances and licensing deals
Kevin Reilly
Keynote Address: Prevnar: "Birth of a Blockbuster"
Rod Richards
A biotech partnering strategy to optimise value
David Tomasso
Roundtable discussion: Partnerships, alliances and licensing deals
Dr Gerd Zettlmeissl
Roundtable discussion: Partnerships, alliances and licensing deals
Day 3 - May 15th 2002
Lawrence Baizer Ph.D
Needle-free injection may enhance immune responses to DNA vaccines
Dr Steve Chatfield
Minimising development costs by efficiently navigating regulatory processes
Dr Jon R. Daugherty
New vaccine technologies: Regulatory issues and perspective
Anne-Marie Georges
Vaccine regulatory challenges in a changing European regulatory environment
Professor Harry B. Greenberg
FluMist‘ – A live, attenuated intra-nasally administered vaccine for influenza
William C. Gruber, MD
Keynote Address: Challenges for clinical trials of new vaccines
Dr Chris Holloway
Regulatory Roundtable feedback
Lendon G. Payne, MD, Ph.D
Epidermal powder immunization with protein and DNA vaccines
Bruce G. Weniger, MD, MPH
Needle-free Delivery Technology Update - Chairman’s introduction
Day 4 - May 16th 2002
Dr Neil Berinstein
Chairman’s introduction
Heather L. Davis Ph.D
CpG DNA as a potent Th1 type immune modulator in cancer vaccines
Dr Adele K. Fielding
Attenuated measles virus - a novel therapy for non-Hodgkin's lymphoma?
Dr Chris Holloway
Cancer vaccines – Regulatory aspects in Europe
Dr Jonathan J. Lewis
Development of a novel vaccine technology: biological and regulatory hurdles and how to deal with them
Dr Søren Mouritsen
AutoVac™ - A vaccine approach that can target any pathogenic self-protein in human disease
